BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

• Autoři: MARCIANO Beatriz E.; HUANG Chiung Yu; JOSHI Gyan; REZAEI Nima; CARVALHO Beatriz Costa; ALLWOOD Zoe; IKINCIOGULLARI Aydan; REDA Shereen M.; GENNERY Andrew; THON Vojtěch; ESPINOSA-ROSALES Francisco; AL-HERZ Walleed; PORRAS Oscar; SHCHERBINA Anna; SZAFLARSKA Anna; KILIC Sebnem; FRANCO Jose L.; GÓMEZ RACCIO Andrea C.; ROXO Persio; ESTEVES Isabel; GALAL Nermeen; GRUMACH Anete Sevciovic; AL-TAMEMI Salem; YILDIRAN Alisan; ORELLANA Julio C.; YAMADA Masafumi; MORIO Tomohiro; LIBERATORE Diana; OHTSUKA Yoshitoshi; LAU Yu-Lung; NISHIKOMORI Ryuta; TORRES-LOZANO Carlos; MAZZUCCHELLI Juliana T.L.; VILELA Maria M.S.; TAVARES Fabiola S.; CUNHA Luciana; PINTO Jorge A.; ESPINOSA-PADILLA Sara E.; HERNANDEZ-NIETO Leticia; ELFEKY Reem A.; ARIGA Tadashi; TOSHIO Heike; DOGU Figen; CIPE Funda; FORMANKOVA Renata; NUNEZ-NUNEZ Enriqueta M.; BEZRODNIK Liliana; MARQUES Jose Goncalo; PEREIRA María I.; LISTELLO Viviana; SLATTER Mary A.; NADEMI Zohreh; KOWALCZYK Danuta; FLEISHER Thomas A.; DAVIES Graham; NEVEN Bénédicte; ROSENZWEIG Sergio D.
• Rok publikování: 2014
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Journal of allergy and clinical immunology
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1016/j.jaci.2014.02.028
• Obor: Imunologie
• Klíčová slova: Primary immunodeficiency; severe combined immunodeficiency; vaccine; BCG; mycobacteria; newborn screening; hematopoietic stem cell transplant; immune reconstitution syndrome
• Popis: Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). The odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. In contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001). Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.